Across TCGA pan-cancer cohorts, LYPLA2P3 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LYPLA2P3’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LYPLA2P3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LYPLA2P3 is over-expressed in tumor.
KIRC and KIRP are the cancer types where LYPLA2P3 tumor–normal differential expression is most reproducible.